Prostate Brachytherapy

Prostate brachytherapy is a form of internal radiotherapy in which the radiation source is placed inside the prostate or very close to it. It can be an effective option in selected cases of localized prostate cancer; however, candidacy should be assessed together with tumor characteristics, urinary symptoms, and coexisting medical conditions. ^[1][2][6]

What exactly does prostate brachytherapy mean?

Brachytherapy aims to deliver radiation not from outside the body, but from a point very close to the tumor. In prostate cancer, there are two main forms of this treatment: low-dose-rate permanent seed brachytherapy and high-dose-rate, or HDR, brachytherapy delivered through temporary catheters. In both approaches, the goal is to deliver a high dose to the prostate tissue while reducing unnecessary exposure to the bladder, rectum, and nearby healthy tissues. For this reason, brachytherapy is regarded as a highly targeted local treatment option in appropriately selected patients. ^[1][2][3]

Prostate brachytherapy is generally considered when the cancer is confined to the prostate or when regional risk remains limited. It may be used alone in low-risk and some intermediate-risk cases, whereas in higher-risk disease it may be combined with external-beam radiation therapy and sometimes hormone therapy. Treatment planning is based not only on the pathology report, but also on PSA level, Gleason score or the current Grade Group classification, imaging findings, and life expectancy. ^[2][6][7]

Who may be a suitable candidate?

This treatment is not equally appropriate for everyone. A very large prostate volume, marked lower urinary tract symptoms, advanced voiding difficulty, certain bowel disorders, or previous pelvic treatment may complicate planning. In particular, for patients being considered for permanent seed brachytherapy, poor urinary flow, urgency, and nocturia must be carefully evaluated because these symptoms may worsen after treatment. Candidate selection is therefore critical not only for treatment success, but also for side-effect management. ^[2][3][4]

Multiparametric prostate MRI, the biopsy report, staging tools such as PSMA PET in selected cases, and fitness for general anesthesia may also influence eligibility. In some patients, brachytherapy is considered an alternative to surgery; in others, it is used as a dose-intensifying addition to external radiotherapy. Which strategy is more appropriate depends on the balance between the risk of cancer spread and the person’s urinary and bowel function. A personalized decision is more valuable than any standard template. ^[2][5][6]

How does the treatment process work?

In permanent seed brachytherapy, small radioactive seeds are placed into the prostate, usually under anesthesia, through thin needles inserted via the perineum. These seeds deliver a controlled dose over weeks or months and usually remain in the body. In HDR brachytherapy, temporary catheters are used to deliver a high dose of radiation for a short period; the source is then withdrawn at the end of the procedure, leaving no permanent radioactive material behind. In both methods, imaging and dose planning are essential for treatment accuracy. ^[1][3][7]

Before the procedure, blood-thinning medications, infection risk, urinary obstruction, and anesthesia-related issues are reviewed. During the first days after treatment, symptoms such as burning with urination, frequent urination, mild perineal pain, or blood in the semen may occur. Most of these effects are temporary; however, inability to urinate, high fever, heavy bleeding, or severe pain should prompt immediate contact with the care team. In some cases, catheterization, marked difficulty urinating, or bowel irritation may develop. ^[2][3][4]

Advantages, limitations, and follow-up

A key advantage of brachytherapy is that, in well-selected patients, it can achieve effective local control while delivering treatment in a relatively focused manner. In some centers, hospital stay may be short, and return to daily life can be faster than after major surgery. Nevertheless, no advanced technology is automatically the best option for every patient; long-term urinary symptoms, changes in sexual function, and bowel side effects can vary substantially from person to person. Expected benefits and possible harms should be discussed realistically. ^[1][4][5]

Follow-up after treatment is usually based on PSA monitoring. The PSA decline after brachytherapy may not be as immediate as after surgery, and temporary fluctuations can occur; for this reason, results must be interpreted correctly by a specialist. Follow-up visits also assess urinary symptoms, bowel complaints, sexual health, and the need for additional imaging when necessary. New urinary retention, recurrent infection, visible blood in the stool, or intolerable pelvic pain should be reported without delay. ^[2][4][6]

The decision to use prostate brachytherapy is made by jointly evaluating tumor stage, prostate volume, urinary symptoms, and overall health status. A shared assessment by urology and radiation oncology teams is important for an individualized treatment plan. ^[1][2][6]

What questions should patients ask when choosing a treatment?

If brachytherapy is being considered, it is useful for patients to ask not only “Am I eligible?” but also which type of brachytherapy is being recommended and why, what the alternatives are, and how existing urinary symptoms may affect the outcome. Expected cancer control, possible late side effects, effects on sexual function, and the follow-up plan should also be discussed clearly. These questions do not complicate treatment; on the contrary, they support better-informed decision-making. In localized prostate cancer, more than one acceptable option may be available, so having balanced information matters. ^[2][4][6]

Another practical issue is how much treatment will affect daily life. Time to return to work, driving, physical activity, sexual life, and medication needs vary from person to person. For some, shorter hospitalization is a major advantage; for others, long-term urinary comfort or the likelihood of bowel side effects may be more important. Clarifying these priorities before treatment helps reduce later regret and supports realistic expectations. ^[1][3][5]